



MAYNE PHARMA EXECUTES ASSET PURCHASE AGREEMENT WITH NOVAN AND EPI HEALTH FOR RHOFADÉ®

- Adds a single source, immediately accretive asset to portfolio of dermatology products
- Aligns with Company mission of expanding access to high quality medicines

4 September 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that one of its US subsidiaries has entered into an asset purchase agreement to acquire the global rights to RHOFADÉ® from Novan, Inc. and EPI Health, LLC. RHOFADÉ® (oxymetazoline hydrochloride) cream 1%. RHOFADÉ® is manufactured pursuant to NDA 208552 and is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. The terms of the deal are US\$8 million in cash at closing plus associated cure costs not to exceed US\$1.5 million. Deal closing is subject to Court approval of the Sale Order.

For the 12 months ending 31 March 2023, EPI Health had approximately US\$12 million in net sales for RHOFADÉ® per their publicly available 10Q filings.

Mayne Pharma's CEO Mr Shawn Patrick O'Brien said: "This acquisition is a great example of how we're able to leverage our existing dermatology infrastructure to add immediately accretive, well-known brands to our portfolio. We're continuing to focus on identifying and taking advantage of strategic expansion opportunities, and RHOFADÉ® fits well with our other products that help patients suffering from rosacea. Our goal, as always, is to give patients access to high quality medications while reducing the burden on prescribers, ultimately allowing us to drive long-term revenue growth and deliver shareholder value."

For further information contact:

Australia:

Craig Haskins

+61 421 029 843

ir@maynepharma.com

USA:

Lisa M. Wilson

T: 917-543-9932

E: ir@maynepharma.com

Authorised for release to the ASX by the Chair

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

RHOFADÉ is a registered trademark of EPI Health, LLC.

Mayne Pharma Group Limited

ABN 76 115 832 963

maynepharma.com

1538 Main North Road, Salisbury South, SA 5106 Australia